ImmuCell Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ImmuCell Corporation (ICCC) on November 4, 2025, covering events occurring on October 29, 2025. The filing details significant changes to the Company's executive leadership and Board of Directors composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Transition: Olivier te Boekhorst assumed the roles of President and Chief Executive Officer effective November 1, 2025. Michael F. Brigham stepped down from these roles, as well as Secretary and Treasurer, to become Special Advisor to the CEO.
- Board Expansion: The Board of Directors voted to expand its size from seven to nine directors.
- New Director Appointments: Olivier te Boekhorst and Timothy C. Fiori (Chief Financial Officer) were elected as directors.
- Officer Appointments: Timothy C. Fiori was elected as Secretary and Treasurer to fill vacancies left by Mr. Brigham.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. Management commentary is limited to the confirmation of the leadership transition and the Board's vote. The Company stated it is not aware of any transactions involving the new officers requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Olivier te Boekhorst's tenure as CEO (November 1, 2025).
- Confirm the new Board size of nine directors and the specific roles of the newly elected directors.
- Review the previously filed 8-Ks from September 30, 2025, and April 7, 2025, for details on compensatory arrangements for Mr. te Boekhorst and Mr. Fiori.
- Check the press release (Exhibit 99.1) for additional context on the strategic rationale for these changes.